These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26675677)

  • 21. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
    Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
    Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
    Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Progress in chemotherapy for advanced gastric cancer].
    Xu RH; Teng KY
    Ai Zheng; 2009 Oct; 28(10):1108-13. PubMed ID: 19799823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective analysis of 56 patients with advanced gastric cancer treated with combination of intravenous and intra-arterial intensified neoadjuvant chemotherapy.
    Li GL; Liu K; Bao Y; Cao JM; Xu J; Wang XL; Wu B; Li JS
    Chin Med J (Engl); 2012 Mar; 125(5):780-5. PubMed ID: 22490574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
    Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
    Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy versus none for resectable gastric cancer.
    Wu AW; Xu GW; Wang HY; Ji JF; Tang JL
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005047. PubMed ID: 17443566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer.
    Takahashi S; Kinoshita T; Konishi M; Nakagouri T; Inoue K; Ono M; Sugitou M; Ohtsu A; Boku N; Yoshida S
    Gastric Cancer; 2001; 4(4):192-7. PubMed ID: 11846062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial.
    Ahmadzadeh A; Seyedian SS; Valizadeh A; Soleimani M; Nazari P; Hamidi H
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):727-732. PubMed ID: 32212800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
    Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ;
    Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neoadjuvant chemotherapy in advanced stomach cancer--a case of complete response].
    Káposztás Z; Cseke L; Kalmár K; Horváth OP
    Magy Seb; 2002 Oct; 55(5):321-4. PubMed ID: 12474518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Taxanes on Treatment Sequence in Gastric Cancer.
    Lorenzen S; Stahl M; Hofheinz RD; Al-Batran SE; Lordick F
    Oncol Res Treat; 2020; 43(1-2):42-47. PubMed ID: 31634892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
    Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
    J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
    Cools-Lartigue J; Jones D; Spicer J; Zourikian T; Rousseau M; Eckert E; Alcindor T; Vanhuyse M; Asselah J; Ferri LE
    Ann Surg Oncol; 2015; 22(6):1858-65. PubMed ID: 25476030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
    Saunders JH; Bowman CR; Reece-Smith AM; Pang V; Dorrington MS; Mumtaz E; Soomro I; Kaye P; Madhusudan S; Parsons SL
    J Surg Oncol; 2017 Jun; 115(7):821-829. PubMed ID: 28257148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five-year survival of Advanced Esophagogastric junction cancer with achieved by complete response preoperative S-1 + CDDP combination therapy and surgical resection.
    Kanazawa Y; Fujita I; Kakinuma D; Kanno H; Arai H; Matsutani T; Hagiwara N; Nomura T; Kato S; Naito Z; Uchida E
    Int Cancer Conf J; 2017 Apr; 6(2):60-64. PubMed ID: 31149472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
    Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
    Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Radiotherapeutic strategies in the multimodal therapy of resectable and nonresectable pancreatic carcinoma].
    Wiegel T; Runkel N; Frommhold H; Rübe C; Hinkelbein W
    Strahlenther Onkol; 2000 Jul; 176(7):299-306. PubMed ID: 10962995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.